# Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)

> **NCT04098406** · PHASE2 · COMPLETED · sponsor: **Clene Nanomedicine** · enrollment: 45 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** CNM-Au8
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04098406
- **Lead sponsor:** Clene Nanomedicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2021-07-13
- **Final completion:** 2021-07-13
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04098406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04098406, "Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04098406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*